glycine-N-acyltransferase like 1Genealiases: GATF-C · GNAT
Q-omics provides the consensus-scored GLYATL1 profile across patient tissues and cancer cell-line models. GLYATL1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GLYATL1 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, GLYATL1 RNA expression shows 16,114 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, and TGCT as cancer lineages where GLYATL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLYATL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLYATL1 survival associations across molecular data types. GLYATL1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLYATL1 RNA expression–survival associations across cancer types. High GLYATL1 expression shows unfavorable associations in LUAD and KICH, but favorable associations in KIRP, KIRC, LIHC and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GLYATL1 RNA expression.
This table summarizes GLYATL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GLYATL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLYATL1 shows lower tumor expression in KIRP, KICH, LIHC and HNSC and higher tumor expression in COAD and BRCA. The KIRP box plot shows higher GLYATL1 RNA expression in normal versus tumor tissue (log2 FC = −3.780, t-test p < 0.001).
This table shows molecular features associated with GLYATL1 in patient tissues and cancer cell lines. In patient samples, GLYATL1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GLYATL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SOFT_TISSUE.
